Search

Objective: We propose a new scoring system (I‐PET) combining whole body scan (WBS) and FDG findings to identify patients who have or are likely to become refractory to radioactive iodine. Design: Retrospective analysis of 142 patients age >18 with differentiated thyroid cancer who had a F‐18 labelled fluoro‐2‐deoxyglucose (18F‐FDG) positron emission tomography (PET) and WBS within a 6‐month period between 2010 and 2020. Pairs of 18F‐FDG PET and WBS were reviewed by three independent nuclear medicine physicians and an I‐PET score was assigned: I‐PET [0]: Iodine −ve/FDG −ve, I‐PET [1]: Iodine +ve/FDG −ve, I‐PET [2]: Iodine +ve/FDG +ve and I‐PET [3]: Iodine −ve/FDG +ve. Patients with FDG +ve lesions (I‐PET [2] and I‐PET [3]) were further classified into groups A and B if SUVmax was ≤5 or >5, respectively. Follow‐up data were obtained by chart review. Progression was defined as structural progression as per RECIST 1.1 or further surgical intervention; or biochemical progression as unstimulated thyroglobulin increasing >20% from baseline. Results: Of 142 patients included in the study 121 patients had follow‐up data available for review. At baseline, 49 patients were classified as I‐PET [0], 10 as I‐PET [1], 16 as I‐PET [2] and 46 as I‐PET [3]. Progression was seen in 11/49 (22%) of I‐PET [0], 4/10 (40%) of I‐PET [1], 10/16 (63%) of I‐PET [2] and 34/46 (74%) of I‐PET [3] (p < 0.001). I‐PET [2B] and I‐PET [3B] had a progression rate of 88% (7/8) and 78% (25/32), respectively. I‐PET [3B] were 9.6 times more likely to commence multikinase inhibitor therapy (p = 0.001) and had 8 times greater mortality (p = 0.003) than patients in other I‐PET groups combined. Conclusion: I‐PET is a simple readily acquired imaging biomarker that potentially enhances the dynamic risk stratification and guide treatment in thyroid cancer. [ABSTRACT FROM AUTHOR]

Objective: We propose a new scoring system (I-PET) combining whole body scan (WBS) and FDG findings to identify patients who have or are likely to become refractory to radioactive iodine., Design: Retrospective analysis of 142 patients age >18 with differentiated thyroid cancer who had a F-18 labelled fluoro-2-deoxyglucose ( 18 F-FDG) positron emission tomography (PET) and WBS within a 6-month period between 2010 and 2020. Pairs of 18 F-FDG PET and WBS were reviewed by three independent nuclear medicine physicians and an I-PET score was assigned: I-PET [0]: Iodine -ve/FDG -ve, I-PET [1]: Iodine +ve/FDG -ve, I-PET [2]: Iodine +ve/FDG +ve and I-PET [3]: Iodine -ve/FDG +ve. Patients with FDG +ve lesions (I-PET [2] and I-PET [3]) were further classified into groups A and B if SUVmax was ≤5 or >5, respectively. Follow-up data were obtained by chart review. Progression was defined as structural progression as per RECIST 1.1 or further surgical intervention; or biochemical progression as unstimulated thyroglobulin increasing >20% from baseline., Results: Of 142 patients included in the study 121 patients had follow-up data available for review. At baseline, 49 patients were classified as I-PET [0], 10 as I-PET [1], 16 as I-PET [2] and 46 as I-PET [3]. Progression was seen in 11/49 (22%) of I-PET [0], 4/10 (40%) of I-PET [1], 10/16 (63%) of I-PET [2] and 34/46 (74%) of I-PET [3] (p < 0.001). I-PET [2B] and I-PET [3B] had a progression rate of 88% (7/8) and 78% (25/32), respectively. I-PET [3B] were 9.6 times more likely to commence multikinase inhibitor therapy (p = 0.001) and had 8 times greater mortality (p = 0.003) than patients in other I-PET groups combined., Conclusion: I-PET is a simple readily acquired imaging biomarker that potentially enhances the dynamic risk stratification and guide treatment in thyroid cancer., (© 2022 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.)